Patent 11759506 was granted and assigned to Voyager Therapeutics on September, 2023 by the United States Patent and Trademark Office.
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.